The testing service is a safe and non-invasive test method that can accelerate and enhance screening, it said in a filing with Bursa Malaysia.
As the exclusive distributor of the kit, MYEG will be making the service – the first of its kind in the Philippine market – available through its joint venture, I-Pay MYEG Philippines Inc, in collaboration with IP Biotech, Inc, a licensed importer of vaccines and medical devices in the country, and Family Vaccine and Specialty Clinics, Inc, one of the largest chain of vaccination clinics in the country that delivers quality healthcare services to Filipinos.
MYEG said the diagnostic kit enables the on-site collection of saliva samples at home or at the workplace by licensed medical professionals, after which samples are then sent to partner laboratories for processing, with test results delivered within one to two working days.
“This saliva-based kit, which has received the approval of the Food and Drug Administration (FDA) of the Philippines and has also been approved in Singapore and Indonesia, can detect the new strains of Covid-19 that have been reported in the UK, South Africa, and Brazil,” it said.
Meanwhile, similar kits have also been granted emergency use authorisation from the US FDA, where the likes of retail giant Costco is pioneering the use of such at-home, mail-in Covid-19 tests.
“Apart from the Philippines, MYEG also plans to deploy a similar approach to testing in Malaysia, pending approval from the relevant regulators for the use of the test kits.
“Making such a hassle-free approach to testing available to the Malaysian public would be very much in line with the convenient, doorstep delivery of a myriad government and ancillary services that MYEG is already known for.
“Furthermore, this effort can help ease the pressure on the country’s frontline workers who have been working tirelessly in the past year,” it said.
In the wake of the outbreak of the Covid-19 virus, MYEG said it has leveraged its strengths and expertise as a leading digital services provider in the region to embark on a number of significant initiatives, guided by an overarching vision to provide a holistic solution to help in the fight against the pandemic.
These initiatives include, among others, a cooperation with Anhui Zhifei Longcom Biopharmaceutical Co Ltd to conduct Phase 3 trials, obtain halal certification and distribute the Chinese company’s vaccine in Malaysia; the provision of MySafeTravel, a digital health pass system to facilitate inbound travellers’ adherence to mandatory Covid-19 testing and quarantine requirements; and the provision of a one-stop portal for the screening of workers in the country.
CLICK HERE FOR THE LATEST DATA ON THE COVID-19 SITUATION IN MALAYSIA